|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Land | ||||||||||||||||||||
| Buildings and improvements | ||||||||||||||||||||
| Tenant improvements | ||||||||||||||||||||
| Lease intangibles | ||||||||||||||||||||
| Real estate assets and lease intangibles held for investment, cost | ||||||||||||||||||||
| Accumulated depreciation and amortization | ||||||||||||||||||||
| Real estate assets and lease intangibles held for investment, net | ||||||||||||||||||||
| Real estate assets held for sale, net | ||||||||||||||||||||
| Real estate assets, net | ||||||||||||||||||||
| Other assets: | ||||||||||||||||||||
| Cash, cash equivalents and restricted cash | ||||||||||||||||||||
| Deferred leasing costs, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Investment in Conduit Pharmaceuticals marketable securities (see Notes 2 & 9) | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Other Assets, Miscellaneous | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Investments held in Trust (see Notes 2 & 9) | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Mortgage notes payable, net | ||||||||||||||||||||
| Mortgage notes payable related to real estate assets held for sale, net | ||||||||||||||||||||
| Mortgage notes payable, total net | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accounts payable and accrued liabilities of SPAC (see Notes 2 & 9) | ||||||||||||||||||||
| Accrued real estate taxes | ||||||||||||||||||||
| Dividends payable - Series D Preferred Stock | ||||||||||||||||||||
| Series D Preferred Stock | ||||||||||||||||||||
| Common Class A | ||||||||||||||||||||
| Total dividends payable - Series D Preferred Stock | ||||||||||||||||||||
| Lease liability, net | ||||||||||||||||||||
| Below-market leases, net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Series D Preferred Stock, $0.01 par value per share; 1,000,000 shares authorized; 973,736 shares issued and outstanding (liquidation preference $25.00 per share) as of June 30, 2026 and as of December 31, 2025 | ||||||||||||||||||||
| Series A Common Stock, $0.01 par value per share, shares authorized: 100,000,000; 1,316,939 shares and 1,314,159 shares were issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Dividends and accumulated losses | ||||||||||||||||||||
| Total stockholders' equity before noncontrolling interest | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND EQUITY | ||||||||||||||||||||
Loading...
